Table 1.

Baseline characteristics of subjects participating in the polyp prevention studies

CharacteristicAntioxidant Polyp Prevention Study* (n = 864)Calcium Polyp Prevention Study (n = 930)Aspirin/Folate Polyp Prevention Study (n = 1,121)
Age ± SD, y61.2 ± 8.361.0 ± 9.157.5 ± 9.6
Male, n (%)684 (79.2)672 (72.3)409 (63.5)
Smoker, n (%)577 (68.3)621 (66.8)638 (57.2)
    Never268 (31.7)309 (33.2)478 (42.8)
    Former389 (46.0)442 (47.5)471 (42.2)
    Current188 (22.3)179 (19.3)167 (15.0)
Treatment
    Placebo214466169
    β-Carotene208
    Vitamin C/E217
    B, C/E225
    Calcium 1,200 mg464
    Aspirin 81 mg only169
    Aspirin 325 mg only167
    Aspirin 81 mg/1 mg folate175
    Aspirin 325 mg/1 mg folate 171
    Folate only 1 mg170
Race, n (%)
    White733 (85.2)791 (85.1)958 (85.5)
    African American58 (6.7)75 (8.1)68 (6.1)
    Hispanic19 (2.2)27 (2.9)61 (5.4)
    Other50 (5.8)37 (4.0)34 (3.0)
BMI, mean (SD)26.9 (4.1)27.4 (4.4)27.4 (4.5)
Total energy intake (SD), calories/day1,955.0 (757.7)2,024 (758.6)1,634 (667.0)
Carbohydrates (SD), g/day201.7 (80.1)219.5 (82.0)185.9 (77.4)
Fat total (SD), g/day86.2 (43.0)87.7 (7)65.1 (34.3)
Fiber (SD), g/day14.2 (7.2)16.4 (7.9)13.3 (6.0)
Folate (SD), mg/day314.3 (165.3)331.3 (168.1)319.9 (156.6)
Red meat intake (SD), servings per day0.54 (0.42)0.48 (0.38)0.36 (0.31)
  • *Study 1 was the Antioxidant Polyp Prevention Study (22).

  • Study 2 was the Calcium Polyp Prevention Study (20).

  • Study 3 the Aspirin Folate Polyp Prevention Study (21).